A. Fandi

Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects.

F. Eschwège, E. Cvitkovic, O. Dupuis, 1995, International journal of radiation oncology, biology, physics.

Phase II trial of chemotherapy with 5‐fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type

J. Armand, E. Cvitkovic, N. Chouaki, 1999, Cancer.

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype

E. Raymond, J. Armand, E. Cvitkovic, 1999 .

Nasopharyngeal cancer: epidemiology, staging, and treatment.

J. Armand, E. Cvitkovic, M. Altun, 1994, Seminars in oncology.

Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.

J. Armand, F. Eschwège, H. Boussen, 1995, The cancer journal from Scientific American.

[Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects].

J. Armand, F. Eschwège, E. Cvitkovic, 1994, Bulletin du cancer.

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type.

J. Armand, F. Eschwège, H. Boussen, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.

M. Ducreux, P. Rougier, J. Armand, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.

E. Raymond, J. Armand, E. Cvitkovic, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

554 Demonstrated efficiency of 5fluorouracil (5FU) continuous infusion (CI) and cisplatin (P) in patients with advanced biliary tract carcinoma

M. Ducreux, P. Rougier, J. Armand, 1995 .